A nonpeptide inhibitor of NGF binding to p75NTR (IC50 ~ 1 μM in CHO cells); binds NGF, not p75NTR. Affinity maybe altered by the presence of TrkA receptors. Neuroprotective.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|1eq. NaOH||7.25||20 with sonication|
Preparing Stock Solutions
The following data is based on the product molecular weight 362.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||13.8 mL||69 mL||137.99 mL|
|1 mM||2.76 mL||13.8 mL||27.6 mL|
|2 mM||1.38 mL||6.9 mL||13.8 mL|
|10 mM||0.28 mL||1.38 mL||2.76 mL|
References are publications that support the biological activity of the product.
Colquhoun et al (2004) Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA. J.Pharmacol.Exp.Ther. 310 505 PMID: 15051797
Eibl et al (2012) Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem.Int. 61 1266 PMID: 23103525
Longo et al (2008) Small molecule modulation of p75 neurotrophin receptor functions. CNS Neurol.Disord.Drug Targets 7 63 PMID: 18289033
If you know of a relevant reference for PD 90780, please let us know.
View Related Products by Target
Keywords: PD 90780, PD 90780 supplier, PD90780, nonpeptide, inhibitors, inhibits, of, NGF, binding, p75, receptor, TrkA, neuroprotective, nerve, growth, factors, Trk, Receptors, 5101, Tocris Bioscience
Citations for PD 90780
Citations are publications that use Tocris products.
Currently there are no citations for PD 90780. Do you know of a great paper that uses PD 90780 from Tocris? Please let us know.
Reviews for PD 90780
There are currently no reviews for this product. Be the first to review PD 90780 and earn rewards!
Have you used PD 90780?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.